Vickerman Investment Advisors Inc. Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Vickerman Investment Advisors Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,933 shares of the biopharmaceutical company’s stock after selling 8,787 shares during the quarter. Vickerman Investment Advisors Inc.’s holdings in Pfizer were worth $1,291,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PFE. Vanguard Group Inc. grew its holdings in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the last quarter. Geode Capital Management LLC grew its holdings in Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank purchased a new position in Pfizer in the fourth quarter worth $2,328,986,000. Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after purchasing an additional 4,167,222 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.5%

NYSE PFE opened at $25.45 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company has a fifty day moving average of $23.72 and a 200 day moving average of $24.82. The company has a market capitalization of $144.66 billion, a PE ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 earnings per share. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. Pfizer’s payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Redburn Atlantic cut their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. Leerink Partners cut their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. TD Cowen lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research note on Tuesday, April 22nd. Finally, Wolfe Research lifted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.